RELATIVE PATIENT PREFERENCES FOR STARTING DAILY, ON-DEMAND, AND LONG-ACTING INJECTABLE HIV PRE-EXPOSURE PROPHYLAXIS AMONG US MEN WHO HAVE SEX WITH MEN, 2021-2022 

This page intends to provide information presented at recent congresses relevant to your unsolicited enquiry. Regulations vary by country, and some information may be off label (not authorised) in your country. Please refer to local product information before prescribing. ViiV Healthcare do not advocate off -label use of their medicines. 

0%
TEMPLATE DESIGN © 2008
www.PosterPresentations.com

Relative patient preferences for starting daily, on
-demand, and long-acting injectable HIV pre-exposure prophylaxis
among US men who have sex with men, 2021
-2022
Travis Sanchez, Rollins School of Public Health, Emory University, Atlanta, GA, USA

And

S. Wilson Beckham
1, Marissa Hannah2, O. Winslow Edwards2, M. Keith Rawlings3, Alex Rinehart3, Supriya Sarkar3, Aaron Siegler2, Patrick S Sullivan2, and Vani Vannappagari3
Background

Methods

Discussion and Conclusions

Few men who have sex with men (MSM) are currently
using daily oral (DO) HIV pre
-exposure prophylaxis (PrEP)
Newer options, such as on-demand (OD) oral and long-
acting injectable (LA) PrEP may improve uptake

OBJECTIVE:
Preferences for starting various PrEP options
were examined among a US nationwide online convenience

sample of MSM

Recruitment
September 2021 to February 2022
Online recruitment through banner ads on social media,
sex
-seeking and gay interest websites and apps
Eligibility
15 years of age or older
Cisgender male
Had oral or anal sex with a man at least once in the past
OR identify as gay/bisexual (15
-17yo only)
US residence
Additional analytic criteria
Oral or anal sex with another man in the past 12 months
No self-report of prior HIV diagnosis
Measures
Scenario based preferences after brief explanation of
PrEP option
“If [PrEP option] were available from your local
doctor and you could access it for free, would you go to your

doctor in the next month to start
[PrEP option]?”
Rank preferences if would start multiple
If current DO user, framed as “would you switch”
Statistical Analysis
Willingness to start LA
-PrEP explored with multivariable
logistic regression with predicted margins approach, for

age, race/ethnicity, insurance and heard of LA
-PrEP.
Adjusted prevalence ratios (
aPR) and 95% confidence
intervals (CI) reported.

There is substantial interest in new PrEP options
Current DO-PrEP users appear to be more aware of and
interested in LA
-PrEP
Although OD-PrEP may be favored by those who are not
taking PrEP, most selected multiple options and preferred

LA
-PrEP
There are few disparities in LA-PrEP interest
Increasing awareness of LA-PrEP may bolster interest in its
use.

These findings highlight the potential role that newer PrEP
options will play in community uptake of PrEP and can

inform patient
-provider decisions about which PrEP options
to consider

1
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2 Rollins School of Public Health, Emory University, Atlanta, GA, USA, 3 ViiV Healthcare, Research Triangle, NC, USAAll Willingness
18.82% (1051/5585)
Ranked First
Daily - 35.39% (372/1051)
Long-Acting - 43.86% (461/1051)
On-Demand - 19.31% (203/1051)
Daily and Long-Acting Willingness
2.83% (158/5585)
Ranked First
Daily - 34.18% (54/158)
Long-Acting - 65.82% (104/158)
On-Demand and Long-Acting Willingness
2.79% (156/5585)
Ranked First
Long-Acting - 62.18% (97/156)
On-Demand - 37.82%, (59/156)
Figure 1. Willingness to start PrEP options among men who have sex with men who are not currently taking daily oral PrEP, AMIS, 2021-2022
Daily and On-Demand Willingness
12.44% (695/5585)
Ranked First
Daily - 60.14% (418/695)
On-Demand - 36.83% (256/695)
Long-Acting
Willingness to Try at Least One PrEP Option
50.22% (2805/5585)
Willingness to Try Each PrEP Option
Daily - 39.37% (2199/5585)
Long-Acting - 26.45% (1477/5585)
On-Demand - 40.11% (2240/5585)
On-Demand Willingness Only
6.05% (338/5585)
Long-Acting Willingness Only
2.00% (112/5585)
Daily Willingness Only
5.28% (295/5585)
Figure 2. Willingness to start PrEP options among men who have sex with men who are currently taking daily oral PrEP, AMIS, 2021-2022
On-Demand and Long-Acting Willingness
20.2% (471/2332)
Ranked First
Long-Acting - 68.15% (321/471)
On-Demand - 31.85% (150/471)
(31.35%,
731/2332)
(46.4%,
1082/2332)
Willing to Switch to at Least One
57.55% (1342/2332)
Wanting to Stay with Daily Oral
30.06% (701/2332)
Long-Acting

Key Information

2021-2022 online nationwide survey with MSM about their
preferences for different PrEP options

Daily oral (DO)
On-demand (OD)
Long-acting injectable (LA)
Among those not currently taking DO-PrEP
50% would start some type of PrEP
OD-PrEP was ranked first
73% of those would start multiple types of PrEP
LA-PrEP was ranked first among people who chose
multiple PrEP options

Among those currently taking DO-PrEP
58% would switch to something else
LA-PrEP was ranked first
Willingness to start LA-PrEP was higher among
Hispanic/Latino MSM not currently using DO-PrEP
Prior awareness of LA-PrEP, regardless of DO-PrEP use
Willingness to start LA-PrEP was lower among
Other/multiple insured MSM not currently using DO-PrEP
5,585 not

currently taking

DO
-PrEP
2,332 currently

taking DO
-PrEP
Example LA
-PrEP
explanation

Connect with Us

Travis.Sanchez@Emory.edu
or +1-404-727-8403
AMIS@Emory.edu
or https://EmoryAMIS.org
@
AmericanMensInternetSurvey
aPR
(CI) = 1.12 (0.93, 1.36)
aPR
(CI) = 1.34 (1.15, 1.56)
Willingness to Use Injectable HIV Pre
-exposure Prophylaxis among United States Men who have Sex with Men, American Men's Internet Survey, 2021
aPR (CI) = 0.85 (0.63,1.14)

aPR (CI) = 0.77 (0.61, 0.98)

aPR (CI) = 1.18 (1.04, 1.33)

aPR
(CI) = 1.16 (1.01, 1.32)
No significant difference by age group. See abstract for Table with full findings.

Results
0%
TEMPLATE DESIGN © 2008
www.PosterPresentations.com

Relative patient preferences for starting daily, on
-demand, and long-acting injectable HIV pre-exposure prophylaxis
among US men who have sex with men, 2021
-2022
Travis Sanchez, Rollins School of Public Health, Emory University, Atlanta, GA, USA

And

S. Wilson Beckham
1, Marissa Hannah2, O. Winslow Edwards2, M. Keith Rawlings3, Alex Rinehart3, Supriya Sarkar3, Aaron Siegler2, Patrick S Sullivan2, and Vani Vannappagari3
Background

Methods

Discussion and Conclusions

Few men who have sex with men (MSM) are currently
using daily oral (DO) HIV pre
-exposure prophylaxis (PrEP)
Newer options, such as on-demand (OD) oral and long-
acting injectable (LA) PrEP may improve uptake

OBJECTIVE:
Preferences for starting various PrEP options
were examined among a US nationwide online convenience

sample of MSM

Recruitment
September 2021 to February 2022
Online recruitment through banner ads on social media,
sex
-seeking and gay interest websites and apps
Eligibility
15 years of age or older
Cisgender male
Had oral or anal sex with a man at least once in the past
OR identify as gay/bisexual (15
-17yo only)
US residence
Additional analytic criteria
Oral or anal sex with another man in the past 12 months
No self-report of prior HIV diagnosis
Measures
Scenario based preferences after brief explanation of
PrEP option
“If [PrEP option] were available from your local
doctor and you could access it for free, would you go to your

doctor in the next month to start
[PrEP option]?”
Rank preferences if would start multiple
If current DO user, framed as “would you switch”
Statistical Analysis
Willingness to start LA
-PrEP explored with multivariable
logistic regression with predicted margins approach, for

age, race/ethnicity, insurance and heard of LA
-PrEP.
Adjusted prevalence ratios (
aPR) and 95% confidence
intervals (CI) reported.

There is substantial interest in new PrEP options
Current DO-PrEP users appear to be more aware of and
interested in LA
-PrEP
Although OD-PrEP may be favored by those who are not
taking PrEP, most selected multiple options and preferred

LA
-PrEP
There are few disparities in LA-PrEP interest
Increasing awareness of LA-PrEP may bolster interest in its
use.

These findings highlight the potential role that newer PrEP
options will play in community uptake of PrEP and can

inform patient
-provider decisions about which PrEP options
to consider

1
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2 Rollins School of Public Health, Emory University, Atlanta, GA, USA, 3 ViiV Healthcare, Research Triangle, NC, USAAll Willingness
18.82% (1051/5585)
Ranked First
Daily - 35.39% (372/1051)
Long-Acting - 43.86% (461/1051)
On-Demand - 19.31% (203/1051)
Daily and Long-Acting Willingness
2.83% (158/5585)
Ranked First
Daily - 34.18% (54/158)
Long-Acting - 65.82% (104/158)
On-Demand and Long-Acting Willingness
2.79% (156/5585)
Ranked First
Long-Acting - 62.18% (97/156)
On-Demand - 37.82%, (59/156)
Figure 1. Willingness to start PrEP options among men who have sex with men who are not currently taking daily oral PrEP, AMIS, 2021-2022
Daily and On-Demand Willingness
12.44% (695/5585)
Ranked First
Daily - 60.14% (418/695)
On-Demand - 36.83% (256/695)
Long-Acting
Willingness to Try at Least One PrEP Option
50.22% (2805/5585)
Willingness to Try Each PrEP Option
Daily - 39.37% (2199/5585)
Long-Acting - 26.45% (1477/5585)
On-Demand - 40.11% (2240/5585)
On-Demand Willingness Only
6.05% (338/5585)
Long-Acting Willingness Only
2.00% (112/5585)
Daily Willingness Only
5.28% (295/5585)
Figure 2. Willingness to start PrEP options among men who have sex with men who are currently taking daily oral PrEP, AMIS, 2021-2022
On-Demand and Long-Acting Willingness
20.2% (471/2332)
Ranked First
Long-Acting - 68.15% (321/471)
On-Demand - 31.85% (150/471)
(31.35%,
731/2332)
(46.4%,
1082/2332)
Willing to Switch to at Least One
57.55% (1342/2332)
Wanting to Stay with Daily Oral
30.06% (701/2332)
Long-Acting

Key Information

2021-2022 online nationwide survey with MSM about their
preferences for different PrEP options

Daily oral (DO)
On-demand (OD)
Long-acting injectable (LA)
Among those not currently taking DO-PrEP
50% would start some type of PrEP
OD-PrEP was ranked first
73% of those would start multiple types of PrEP
LA-PrEP was ranked first among people who chose
multiple PrEP options

Among those currently taking DO-PrEP
58% would switch to something else
LA-PrEP was ranked first
Willingness to start LA-PrEP was higher among
Hispanic/Latino MSM not currently using DO-PrEP
Prior awareness of LA-PrEP, regardless of DO-PrEP use
Willingness to start LA-PrEP was lower among
Other/multiple insured MSM not currently using DO-PrEP
5,585 not

currently taking

DO
-PrEP
2,332 currently

taking DO
-PrEP
Example LA
-PrEP
explanation

Connect with Us

Travis.Sanchez@Emory.edu
or +1-404-727-8403
AMIS@Emory.edu
or https://EmoryAMIS.org
@
AmericanMensInternetSurvey
aPR
(CI) = 1.12 (0.93, 1.36)
aPR
(CI) = 1.34 (1.15, 1.56)
Willingness to Use Injectable HIV Pre
-exposure Prophylaxis among United States Men who have Sex with Men, American Men's Internet Survey, 2021
aPR (CI) = 0.85 (0.63,1.14)

aPR (CI) = 0.77 (0.61, 0.98)

aPR (CI) = 1.18 (1.04, 1.33)

aPR
(CI) = 1.16 (1.01, 1.32)
No significant difference by age group. See abstract for Table with full findings.

Results

NP-GBL-HVX-WCNT-220037 September 2022 

Report an adverse event

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.